New Pfizer/BioNTech vaccine variant shows enhanced protection against COVID-19 hospitalization

Study demonstrates that the BNT162b2 SARS-CoV-2 XBB1.5 variant-modified vaccine significantly reduces the risk of COVID-19-related hospitalizations and ambulatory visits, outperforming previous vaccine versions in the face of evolving virus strains.

Related Keywords

United States ,California , ,Drug Administration ,Centers For Disease ,Ambulatory Visits ,Image Credit ,Corona Borealis Studio ,Disease Control ,Kaiser Permanente Southern California ,California Immunization Registry ,Coronavirus Disease Covid 19 ,Vaccine ,Coronavirus ,Efficacy ,Wood ,Healthcare ,Hospital ,Research ,Espiratory ,Ibonucleic Acid ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,